Global Montelukast Intermediate Market Research Report Forecast to 2023

Global Montelukast Intermediate Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria) - Forecast till 2023

Market analysis
The Global Montelukast Intermediate Market has been used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma by Montelukast which is a leukotriene receptor antagonist (LTRA)The collective presence of generics and the opposing part of the presence of stringent regulatory policies and the tall prices of manufacturing building blocks for active pharmaceutical ingredients which are likely to hamper the market development during the forecast period. Additionally, montelukast is designated for the handling of periodic and recurrent allergic rhinitis. The important aspects pouring the market evolution are worldwide rising commonness of allergic rhinitis, urticaria, asthma, bronchospasm, burgeoning pharmaceutical industry attached with the rising call from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration.

Market segmentation
The segmentation for Global Montelukast Intermediate Market is given by the influences describing the market progress which are worldwide increasing frequency of allergic rhinitis, and urticaria asthma, bronchospasm mushrooming pharmaceutical industry coupled with the cumulative demand from API manufacturers, and montelukast patent termination along with the snowballing presence of generics. The global montelukast transitional Market is also provided by application which can thus be classified into three types, viz; bronchospasm, and urticaria. asthma and allergic rhinitis. The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are gone and 250,000 asthma deaths are informed worldwide every year. In the year 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries LMICs) among the foremost causes of premature mortality (YLL). The market development in the European region is mostly due to the existence of huge pharmaceutical companies and sophisticated healthcare substructure and the rising frequency of asthma and allergic rhinitis in the US and Canada. About six million children under the age of 18 have asthma being more mutual in children than adults. Also, one in 13 people is living with asthma and is more common in adult women than adult men. Hence, the swelling burden of asthma is powering the demand for montelukast and is supporting in the market growth.

Regional analysis
Geographically, The Global Montelukast Intermediate Market is segmented and targeted into global regions like Americas, Asia-Pacific, Middle East and Africa along with the European market.
Additionally, North America is expected to lead the market. Furthermore, The Global Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.
It is forecasted that Europe currently holds a substantial share in the global Montelukast Intermediate market. The reasons responsible for the market progress in this region are poor air quality due to high fuel release and is growing the occurrence of chronic obstructive pulmonary disease (COPD), asthma, allergy and in the UK, Germany, and France. The Middle East and Africa market are predictable to hold the minimum share in the global Montelukast Intermediate market. In this region, the Middle East is expected to control due to the presence of countries such as Egypt, Saudi Arabia, and others. Asia-Pacific is likely to characterize a hopeful outlook over the forecast period due to the mounting geriatric population along with the increasing prevalence of respiratory diseases. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an projected 15 to 20 Million. According to the WHO, presently, there are about 3 Million asthmatics in Japan of whom 7%have severe, and 30% have moderate asthma. The European Respiratory Society stated that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the maximum rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal specified that the commonness of allergic diseases in Europe is high.

Major players
Companies like P.G. Shah & Co., Manus Aktteva Biopharma LLP, VIVAN Life Sciences, P.G. Shah & Co. and Ortin Laboratories Limited., etc. are some of the major players in the global Montelukast Intermediate market.


1Executive Summary
1.1Market Attractiveness Analysis
2Market Introduction
2.1Definition
2.2Scope of the Study
2.3Assumptions
2.4Market Structure
3Research Methodology
3.1Research Process
3.2Primary Research
3.3Secondary Research
3.4Market Size Estimation
3.5Forecast Model
4Market Dynamics
4.1Introduction
4.2Drivers
4.2.1Worldwide Rising Prevalence of Asthma, Bronchospasm, Allergic Rhinitis, and Urticaria
4.2.2Burgeoning Pharmaceutical Industry Coupled with the Growing Demand from API Manufacturers
4.2.3Montelukast Patent Expiration Along with the Increasing Presence of Generics
4.3Restraints
4.3.1Presence of Stringent Regulatory Policies
4.3.2High Cost of Manufacturing Building Blocks for APIs
4.4Opportunity
4.4.1Ongoing Research and Development Activities
5Market Factor Analysis
5.1Value Chain Analysis
5.1.1Raw Material Sourcing
5.1.2Manufacturing
5.1.3Distribution & Sales
5.1.4End Users
5.2Supply Chain Analysis
5.2.1Raw Material Manufacturer
5.2.2Montelukast Intermediate Manufacturer
5.2.3Importer
5.2.4Distributors
5.2.5Final Product Manufacturer/Customer
5.3Porters Five Forces Model
5.3.1Threat of New Entrants
5.3.2Bargaining Power of Suppliers
5.3.3Bargaining Power of Buyers
5.3.4Threat of Substitutes
5.3.5Intensity of Rivalry
5.4Investment Opportunities
5.5Pricing Analysis
5.6Clinical Trials
5.6.1Overview
5.7Patent Analysis
5.8Key Customers
5.9Regulatory Scenario
5.1Pricing Evolution
5.11Manufacturing Processes
5.11.1Biological Method
5.11.2Chemical Method
5.12Specifications and Purity Requirement
6Global Montelukast Intermediate Market, By Application
6.1Overview
6.2Asthma
6.3Allergic Rhinitis
6.4Bronchospasm
6.5Urticaria
7Global Montelukast Intermediate Market, by Region
7.1Overview
7.2Americas
7.2.1North America
7.2.1.1US
7.2.1.2Canada
7.2.2Latin America
7.3Europe
7.3.1Western Europe
7.3.1.1UK
7.3.1.2France
7.3.1.3Spain
7.3.1.4Germany
7.3.1.5Italy
7.3.1.6Rest of Western Europe
7.3.2Eastern Europe
7.4Asia-Pacific
7.4.1China
7.4.2India
7.4.3Japan
7.4.4Rest of Asia-Pacific
7.5Middle East & Africa
7.5.1Middle East
7.5.2Africa
8Competitive Landscape
8.1Introduction
8.2Major Players in the Global Montelukast Intermediate Market
9Company Profiles
9.1VIVAN Life Sciences
9.1.1Financial Overview
9.1.2Products/Services Offered
9.1.3Key Developments
9.1.4SWOT Analysis
9.1.5Key Strategies
9.2P.G. Shah & Co.
9.2.1Company Overview
9.2.2Financial Overview
9.2.3Products/Services Offered
9.2.4Key Developments
9.2.5SWOT Analysis
9.2.6Key Strategies
9.3Manus Aktteva Biopharma LLP
9.3.1Company Overview
9.3.2Financial Overview
9.3.3Products/Services Offered
9.3.4Key Developments
9.3.5SWOT Analysis
9.3.6Key Strategies
9.4Ortin Laboratories Limited
9.4.1Company Overview
9.4.2Financial Overview
9.4.3Products/Services Offered
9.4.4Key Developments
9.4.5SWOT Analysis
9.4.6Key Strategies
10Appendix
10.1References
10.2Related Reports

List Of Tables



TABLE 1CLINICAL TRIALS
TABLE 2PRICING RANGE FOR MONTELUKAST INTERMEDIATE (USD/KG)
TABLE 3GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 4GLOBAL MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 20152023 (KG)
TABLE 5GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ASTHMA, BY REGION, 20152023 (USD THOUSAND)
TABLE 6GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ALLERGIC RHINITIS, BY REGION, 20152023 (USD THOUSAND)
TABLE 7GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR BRONCHOSPASM, BY REGION, 20152023 (USD THOUSAND)
TABLE 8GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR URTICARIA, BY REGION, 20152023 (USD THOUSAND)
TABLE 9GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 20152023 (USD THOUSAND)
TABLE 10GLOBAL: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 20152023 (KG)
TABLE 11AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 20152023 (USD THOUSAND)
TABLE 12AMERICAS: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 20152023 (KG)
TABLE 13AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 14AMERICAS: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 20152023 (KG)
TABLE 15NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 16NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 20152023 (KG)
TABLE 17NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 18US: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 19CANADA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 20LATIN AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 21EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 20152023 (USD THOUSAND)
TABLE 22EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 20152023 (KG)
TABLE 23EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 24EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 20152023 (KG)
TABLE 25WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 26WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 20152023 (KG)
TABLE 27WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 28UK: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 29FRANCE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 30SPAIN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 31GERMANY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 32ITALY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 33REST OF WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 34EASTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 35ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 36ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 20152023 (KG)
TABLE 37ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 38ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 20152023 (KG)
TABLE 39CHINA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 40INDIA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 41JAPAN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 42REST OF ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 43MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 20152023 (USD THOUSAND)
TABLE 44MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 20152023 (KG)
TABLE 45MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 46MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 20152023 (KG)
TABLE 47MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)
TABLE 48MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20152023 (USD THOUSAND)

List Of Figures



FIGURE 1MARKET SYNOPSIS
FIGURE 2MARKET ATTRACTIVENESS ANALYSIS: GLOBAL MONTELUKAST INTERMEDIATE MARKET
FIGURE 3GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2017 (%)
FIGURE 4GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 20162023 (USD THOUSANDS)
FIGURE 5GLOBAL MONTELUKAST INTERMEDIATE MARKET: MARKET STRUCTURE
FIGURE 6RESEARCH PROCESS OF MRFR
FIGURE 7TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 8MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET
FIGURE 9VALUE CHAIN: GLOBAL MONTELUKAST INTERMEDIATE MARKET
FIGURE 10SUPPLY/VALUE CHAIN: GLOBAL MONTELUKAST INTERMEDIATE MARKET
FIGURE 11PORTERS FIVE FORCES ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET
FIGURE 12PROCESS 1
FIGURE 13PROCESS 2
FIGURE 14PROCESS 3
FIGURE 15PROCESS 4
FIGURE 16PROCESS 5
FIGURE 17GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2017 (%)
FIGURE 18GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2017 & 2023 (USD THOUSAND)
FIGURE 19GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%)
FIGURE 20GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2017 & 2023 (USD THOUSAND)
FIGURE 21AMERICAS: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%)
FIGURE 22EUROPE: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%)
FIGURE 23ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 24MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%)

Global Hemostasis Diagnostic Analyzers and Reagent Market for over 40 Tests: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

This comprehensive seven-country report contains 650 pages, 150 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation

USD 27500 View Report

Global Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Americas, EMEA, APAC--A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation

This new 68-country report is available by region, country, market segment, section, or individual test. The report is designed to help current suppliers and potential market entrants identify and

USD 45000 View Report

Global Montelukast API Market Research Report Forecast to 2023

Montelukast API Market Research Report - Global Forecast till 2023Market AnalysisAn orally offered leukotriene receptor antagonist that used widely for the treatment of asthma is Montelukast API. Respiratory problems related

USD 4450 View Report

Global Montelukast Methyl Ester (CAS 855473-51-7) Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Montelukast Methyl Ester is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available